CD8A and neoplasm: To overcome this defect, Sanz-Ortega et al. (2019) designed a magnetic targeting therapy for T cells by first synthesizing 12.5 nm diameter magnetic nanoparticles (MNP) with an iron oxide core and 3-APS coating, and attaching them to OT-I CD8+ T cells without affecting the antigen-specific CD8+ T cell anti-tumor activity, and relaying them into a homozygous mouse model.